Skip to content

Pfizer PFE Other Income (Expense)

Discontinued — last reported Q1 '24

Other Income (Expense) at other companies

Eli Lilly logo
Eli LillyLLY
-$65M+72.8%
Amgen logo
AmgenAMGN
$75M-95.1%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$456K-198%
Incyte logo
IncyteINCY
$2.77M-65.7%
Exelixis logo
ExelixisEXEL
$219K+189%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$6.26M+112%

Segments

By segment

See full
Biopharma$116M+48.7%

Other financials

Income statement

See full
Revenue$14.5B+5.4%
Gross profit$10.9B+0.3%
Net income$2.7B-9.4%
EPS (diluted)$0.47-9.6%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$143.68B+11.1%
Enterprise value$206.35B+9.2%
P/E11.9×
P/S2.3×+0.2×

Profitability

See full
Gross margin73.5%+1.2pp
Net margin15.7%
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:InterestRevenueExpenseNet.

The official record: Pfizer’s 10-Q, filed May 8, 2024, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pfizer's other income (expense)?
Pfizer (PFE) reported other income (expense) of -$661M in Q1 2024.
How has Pfizer's other income (expense) changed year-over-year?
Pfizer's other income (expense) decreased by 368.8% year-over-year, from -$141M to -$661M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.